Published Date: 02/23/2022
Expiration Date: 11/18/2024
Since this training was published, the federal requirement for practitioners to have a waiver (commonly referred to as the X-Waiver) to prescribe buprenorphine was removed. Additionally, practitioners no longer need to file a notice of intent (NOI) and the limit on the number of patients a practitioner can treat with buprenorphine has been removed. Learn more about these federal changes here.
This one-hour course will teach providers the basics of how to prescribe buprenorphine to treat opioid use disorder. It will discuss the new federal buprenorphine practice guidelines and explain how providers can submit a Notification of Intent to obtain an X-waiver to prescribe buprenorphine. This course will be tailored for primary care and rural health providers.
We also offer case studies, not CE accredited:
?Disclaimer
Effective June 27, 2023 the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) announced a one-time requirement of 8 hours of training on the treatment and management of patients with opioid or other substance use disorders for practitioners who are applying for or renewing their DEA license. This 1-hour ACCME-accredited course meets the DEA/SAMHSA requirement.
Judy Griffin, MD is board-certified in internal medicine and works as a primary care physician and buprenorphine provider at REACH in Ithaca, NY. She serves as the Director of Research at REACH Medical and is the Director of the Rural Health Equity Training Collaborative (RHETC). Dr. Griffin also holds an appointment as a Clinical Instructor in Medicine at Weill Cornell Medical College and is a member of the Criminal Justice-Alternatives to Incarceration Advisory Board for Tompkins County.
